Divya Ahuja, MD
Infectious Disease · Columbia, SCNPI 1134105760
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $163 of the $192 with a category attached, or 84.9%. Dynavax Technologies Corporation accounts for 64.5% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $153 and has fallen 89.5% since, to $16 in 2025. That places this record below the midpoint for infectious disease clinicians in SC, where the typical reported total is $781.
Across 4 payments — averaging $48.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dynavax Technologies Corporation$124
- Astellas Pharma US Inc$29
- Johnson & Johnson$23
- Gilead$16
Across 6 payments — averaging $48,416 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viiv Healthcare Company$290K
What the payments were for
- Food & beverage$16385%
- Education$2915%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dynavax Technologies Corporation | 1 | $124 |
| Astellas Pharma US Inc | 1 | $29 |
| Johnson & Johnson | 1 | $23 |
| Gilead | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Heplisav-B$124
How this compares
$192 in reported general payments places this provider in the 15th percentile of 102 infectious disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 363 | $1,417,638 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 130 | $474,772 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 65 | $226,557 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 38 | $181,163 |
| PrezcobixDarunavir/Cobicistat | 71 | $176,128 |
| TivicayDolutegravir Sodium | 79 | $169,242 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 25 | $94,076 |
| DescovyEmtricitabine/Tenofov Alafenam | 29 | $64,730 |
| PifeltroDoravirine | 20 | $35,139 |
| Darunavir | 24 | $13,279 |
| Vancomycin Hcl | 16 | $4,858 |
| Cefepime Hcl | 17 | $3,190 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $2,303 |
| Amikacin Sulfate | 19 | $2,194 |
| Ritonavir | 23 | $1,917 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $16 | $1,576,445417 claims |
| Johnson & JohnsonPrezcobix | $23 | $176,12871 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 102 infectious disease providers in South Carolina.
Other infectious disease in Columbia
- Helmut AlbrechtColumbia$5K
- Eric BrenerColumbia$2K
- Wajid SiddiquiColumbia$2K
- Pamela BaileyColumbia$2K
- Tameka FunnyColumbia$1K
- Addie SpierColumbia$781
- Sharon WeissmanColumbia$691
- Edwin HayesColumbia$626
- William WootenColumbia$608
- Timothy HenkelHilton Head Island$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.